v3.26.1
Nature of the Business and Basis of Presentation - Additional Information (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Apr. 28, 2025
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Apr. 30, 2025
shares
Sale of Stock                  
Common stock, shares issued   63,556,065       63,556,065   49,316,287  
Common Stock Value Per Share | $ / shares $ 0.0001 $ 0.0001       $ 0.0001   $ 0.0001  
Net loss | $   $ 55,765 $ 40,368 $ 32,134 $ 38,169 $ 96,133 $ 70,303    
Net cash used in operating activities | $           (67,737) $ (38,916)    
Cash and cash equivalents, and investments | $   461,200       461,200      
Cash and cash equivalents | $   107,250       107,250   $ 88,438  
Investments | $   $ 353,955       $ 353,955   $ 247,720  
Aerovate Therapeutics, Inc.                  
Sale of Stock                  
Reverse stock split 1-for-35                
Convertible Notes                  
Sale of Stock                  
Proceeds from issuance of convertible notes | $ $ 95,000                
Accrued interest | $ $ 8,300                
Pre-Merger Jade Common Stock                  
Sale of Stock                  
Common stock, shares issued 43,947,116                
Common stock warrants exercisable 12,305,898                
Common Stock Value Per Share | $ / shares $ 5.9407                
Preferred stock convertible ratio 0.6311                
Pre-Funded Warrants                  
Sale of Stock                  
Number of pre-funded warrants exercised for common stock 12,305,898                
Warrant exercise price per share | $ / shares $ 5.9406                
Aggregate amount of pre funded warrant | $ $ 334,200                
Pre-Funded Warrants | Aerovate Therapeutics, Inc.                  
Sale of Stock                  
Number of pre-funded warrants exercised for common stock 7,766,247                
Common Stock | Aerovate Therapeutics, Inc.                  
Sale of Stock                  
Common stock, shares issued 27,734,940                
Series Seed Convertible Preferred Stock                  
Sale of Stock                  
Preferred stock, par value | $ / shares $ 0.0001                
Convertible shares                 12,622
Series A Preferred Stock                  
Sale of Stock                  
Common Stock Value Per Share | $ / shares $ 0.0001                
Convertible shares 1,000                
Preferred stock convertible ratio 0.0006311 1       1      
Shares to be issued in denominator for calculation 1,000